Accuray Reports Fourth Quarter and Fiscal 2025 Financial Results

Rhea-AI Summary

Accuray (NASDAQ: ARAY) reported its Q4 and fiscal 2025 results with mixed performance. Q4 revenue decreased 5% to $127.5 million, while full-year revenue grew 3% to $458.5 million. The company posted Q4 net income of $1.1 million compared to $3.4 million in the prior year, while recording a full-year net loss of $1.6 million, improved from a $15.5 million loss in FY24.

Service revenue showed strength with a 4% increase in both Q4 and full-year results. The company successfully completed a debt refinancing and maintained a book-to-bill ratio of 1.2. For FY26, Accuray projects revenue between $471-485 million and adjusted EBITDA of $31-35 million.

Positive

• Service revenue grew 4% both quarterly and annually
• Full-year revenue increased 3% to $458.5 million
• Adjusted EBITDA improved to $28.3 million from $19.7 million year-over-year
• Successfully completed debt refinancing with strategic partner
• Book-to-bill ratio maintained at 1.2, indicating healthy demand
• Operating expenses decreased 2% for full fiscal year
• Gross margin improved to 30.6% in Q4 from 28.6% year-over-year

Negative

• Q4 revenue declined 5% year-over-year to $127.5 million
• Q4 product revenue decreased 11% compared to prior year
• Operating expenses increased 10% in Q4 year-over-year
• Order backlog declined 12.4% from prior year to $427.0 million
• Cash position decreased by $20.8 million from previous quarter
• Posted full-year net loss of $1.6 million

News Market Reaction – ARAY

-2.01% 1.8x vol

3 alerts

-2.01% News Effect

-2.6% Trough Tracked

-$3M Valuation Impact

$153M Market Cap

1.8x Rel. Volume

On the day this news was published, ARAY declined 2.01%, reflecting a moderate negative market reaction. Argus tracked a trough of -2.6% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $153M at that time. Trading volume was above average at 1.8x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Strong Service Growth; Debt Refinancing Complete; Company Issues FY26 Guidance

MADISON, Wis., Aug. 13, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal 2025, ended June 30, 2025.

Key Fiscal Fourth Quarter Highlights

• Net revenue was $127.5 million, a decrease of 5 percent from the prior year period.
• Net income was $1.1 million compared to net income of $3.4 million in the prior year period.
• Adjusted EBITDA was $9.4 million compared to $10.1 million in the prior year period.
• Order book-to-bill at 1.2

Key Fiscal Year 2025 Highlights

• Net revenue was $458.5 million, an increase of 3 percent from the prior fiscal year
• Net loss was $1.6 million, compared to net loss of $15.5 million in the prior fiscal year
• Adjusted EBITDA was $28.3 million compared to $19.7 million in the prior fiscal year
• Order book-to-bill at 1.2

"We continued to advance our strategy of innovation, access and service growth within the quarter and I am proud of how we navigated a challenging environment both within the quarter and for the fiscal year," said Suzanne Winter, President and Chief Executive Officer. "In addition to annual revenue growth, strong service performance and adjusted EBITDA margin expansion, we successfully completed a refinancing of our debt with a strong partner that is invested in our long-term success."

Fiscal Fourth Quarter Results

Total net revenue was $127.5 million for the fourth quarter of fiscal 2025, or a decrease of 5 percent, as compared to $134.3 million in the prior fiscal year fourth quarter. Product revenue totaled $70.7 million, or a decrease of 11 percent, as compared to $79.7 million in the prior fiscal year fourth quarter, while service revenue totaled $56.8 million, or an increase of 4 percent, as compared to $54.6 million in the prior fiscal year fourth quarter.

Total gross profit in the fourth quarter of fiscal 2025 was $39.0 million, or 30.6 percent of net revenue, as compared to total gross profit of $38.5 million, or 28.6 percent of net revenue in the prior fiscal year fourth quarter.

Operating expenses were $34.7 million in the fourth quarter of fiscal 2025, or an increase of 10 percent, as compared to $31.6 million in the prior fiscal year fourth quarter.

Net income was $1.1 million, or $0.01 per share, in the fourth quarter of fiscal 2025, as compared to a net income of $3.4 million, or $0.03 per share, in the prior fiscal year fourth quarter. Adjusted EBITDA was $9.4 million in the fourth quarter of fiscal 2025 compared to $10.1 million in the prior fiscal year fourth quarter.

Ending order backlog as of June 30, 2025 was $427.0 million, 5.6 percent lower from the third quarter of fiscal 2025, and 12.4 percent lower than at the end of the prior fiscal year fourth quarter.

Cash, cash equivalents, and short-term restricted cash were $58.0 million as of June 30, 2025, a decrease of $20.8 million from March 31, 2025.

Fiscal Year 2025 Highlights

Total net revenue was $458.5 million for fiscal 2025, or an increase of 3 percent, as compared to $446.6 million in the prior fiscal year period. Product revenue totaled $237.6 million, or an increase of 1 percent, as compared to $234.2 million in the prior fiscal year period. Service revenue totaled $220.9 million, or an increase of 4 percent, as compared to $212.4 million in the prior fiscal year period.

Total gross profit was $147.0 million for fiscal 2025, or 32.1 percent of net revenue, as compared to total gross profit of $142.9 million, or 32.0 percent of net revenue in the prior fiscal year period.

Operating expenses were $139.1 million for fiscal 2025, or a decrease of 2 percent, as compared to $142.4 million for the prior fiscal year period. 

GAAP net loss was $1.6 million, or $0.02 per share, for the fiscal 2025, as compared to a net loss of $15.5 million, or $0.16 per share, in the prior fiscal year period. Adjusted EBITDA was $28.3 million for fiscal 2025, as compared to $19.7 million in the prior fiscal year period.

"Our fourth quarter and full year financial results demonstrate the resilience of our team despite macroeconomic challenges and continuing tariff uncertainty. We made steady operational progress while continuing to drive customer adoption through the expansion of our product portfolio. We also announced refinancing plans with a partner committed to advancing our global business. I look forward to working with them, together with the global Accuray team, to execute on our core strategies for driving consistent growth," said Ali Pervaiz, Chief Financial Officer at Accuray.

Fiscal Year 2026 Financial Guidance

Accuray's financial guidance is based on current expectations. The following statements are forward-looking and actual results could differ materially depending on market and economic conditions, supply chain disruption, and the factors set forth under "Safe Harbor Statement" below.

The Company is introducing guidance for fiscal year 2026 as follows:

• Total net revenue is expected in the range of $471 million to $485 million.
• Adjusted EBITDA is expected in the range of $31 million to $35 million.

Guidance for Adjusted EBITDA, a non-GAAP financial measure excludes depreciation and amortization, stock-based compensation expense, interest expense and provision for income taxes. For more information regarding the non-GAAP financial measures discussed in this press release, please see "Use of Non-GAAP Financial Measures" below.

Conference Call Information

Accuray will host a conference call beginning at 1:30 p.m. PT/4:30 p.m. ET today to discuss results for the fourth quarter of fiscal 2025 as well as recent corporate developments. Conference call dial-in information is as follows:

• U.S. callers: (888) 999-5318
• International callers: (848) 280-6460

Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Investor Relations section of Accuray's website, www.accuray.com. There will be a slide presentation accompanying today's event which can also be accessed on the company's Investor Relations page at www.accuray.com.

In addition, a taped replay of the conference call will be available beginning approximately one hour after the call's conclusion and will be available for seven days. The replay number is (877) 344-7529 (USA), or (412) 317-0088 (International), Conference ID: 3326908. An archived webcast will also be available on Accuray's website until Accuray announces its results for the first quarter of fiscal 2026.

Use of Non-GAAP Financial Measures

Accuray reports its financial results in accordance with generally accepted accounting principles in the United States ("GAAP") and the rules of the SEC. To supplement its financial statements prepared and presented in accordance with GAAP, Accuray uses certain non-GAAP financial measures, such as adjusted EBITDA.

Accuray has supplemented its GAAP net income (loss) with a non-GAAP measure of adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation, changes to the fair value of warrant liability, ERP and ERP related expenditures and restructuring charges ("adjusted EBITDA"). The calculation of adjusted EBITDA also excludes certain non-recurring, irregular and one-time items. Management believes that this non-GAAP financial measure provides useful supplemental information to management and investors regarding the performance of the company and facilitates a meaningful comparison of results for current periods with previous operating results. A reconciliation of GAAP net income (loss) (the most directly comparable GAAP measure) to non-GAAP adjusted EBITDA is provided in the schedules below.

There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP.

About Accuray

Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. 

Safe Harbor Statement

Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the company's guidance and future results of operations, including expectations regarding: total net revenue and adjusted EBITDA; the company's ability to deliver sustained performance and execute on its strategies; expectations regarding the impact of tariffs as well as mitigation efforts by the company; expectations regarding the company's refinancing and refinancing partner; the company's ability to navigate supply chain, logistics, macroeconomic, and foreign exchange challenges; the company's ability to achieve its longer-term goals; expectations regarding the company's China joint venture; expectations related to the amount and timing of realizing deferred margin from the company's China joint venture; expectations with respect to strategic partnerships and collaborations; expectations related to the markets and regions in which the company operates; expectations regarding new product introductions and innovations; expectations regarding service business growth and its ability to serve as a growth driver; expectations regarding installed base growth; and the company's ability to advance patient care and offer value to its customer. These forward-looking statements involve risks and uncertainties. If any of these risk or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results express or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the effect of the global macroeconomic environment on the operations of the company and those of its customers and suppliers; disruptions to our supply chain, including increased logistics costs; the company's ability to achieve widespread market acceptance of its products; substantial outstanding indebtedness and its ability to maintain compliance with financial covenants related to its debt; the effect of enhanced international tariffs on the company; the company's ability to realize the expected benefits of the China joint venture and other partnerships; risks inherent in international operations; the company's ability to maintain or increase its gross margins on product sales and services; delays in regulatory approvals or the development or release of new offerings; the company's ability to meet the covenants under its credit facilities; the company's ability to convert backlog to revenue; and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on May 2, 2025, and as updated periodically with the company's other filings with the SEC.

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Aman Patel, CFA	Beth Kaplan
Investor Relations, ICR-Westwicke	Public Relations Director, Accuray
+1 (443) 450-4191	+1 (408) 789-4426
aman.patel@westwicke.com	bkaplan@accuray.com

Financial Tables to Follow

 

Accuray Incorporated Condensed Consolidated Statements of Operations (in thousands, except per share data) (Unaudited)
		Three Months Ended June 30,								Twelve Months Ended June 30,
		2025				2024				2025				2024
Net revenue:
Products		$	70,702			$	79,673			$	237,580			$	234,164
Services			56,841				54,616				220,925				212,387
Total net revenue			127,543				134,289				458,505				446,551
Cost of revenue:
Cost of products			51,254				55,084				162,569				161,061
Cost of services			37,310				40,753				148,969				142,569
Total cost of revenue			88,564				95,837				311,538				303,630
Gross profit			38,979				38,452				146,967				142,921
Operating expenses:
Research and development			11,470				9,529				47,942				49,732
Selling and marketing			11,409				10,696				43,315				42,619
General and administrative			11,866				11,410				47,871				50,066
Total operating expenses			34,745				31,635				139,128				142,417
Income from operations			4,234				6,817				7,839				504
Income from equity method investment			885				810				4,714				1,838
Interest expense			(4,226)				(2,895)				(12,954)				(11,624)
Gain on extinguishment of debt			1,475				—				1,475				—
Loss from change in fair value of warrant liability			(499)				—				(499)				—
Other income (expense), net			202				(874)				559				(2,538)
Income (loss) before provision for income taxes			2,071				3,858				1,134				(11,820)
Provision for income taxes			948				471				2,725				3,725
Net income (loss)		$	1,123			$	3,387			$	(1,591)			$	(15,545)
Net income (loss) per share - basic		$	0.01			$	0.03			$	(0.02)			$	(0.16)
Net income (loss) per share - diluted		$	0.01			$	0.03			$	(0.02)			$	(0.16)
Weighted average common shares used in computing income (loss) per share:
Basic			106,702				99,585				102,768				98,272
Diluted			108,891				101,028				102,768				98,272

 

Accuray Incorporated Condensed Consolidated Balance Sheets (in thousands) (Unaudited)
		June 30,				June 30,
		2025				2024
Assets
Current assets:
Cash and cash equivalents		$	57,416			$	68,570
Restricted cash			574				485
Accounts receivable, net			83,192				92,001
Inventories			141,020				138,324
Prepaid expenses and other current assets			33,501				23,006
Deferred cost of revenue			1,762				850
Total current assets			317,465				323,236
Noncurrent assets:
Property and equipment, net			28,658				24,774
Investment in joint venture			4,612				9,826
Operating lease right-of-use assets			33,115				33,773
Goodwill			57,802				57,672
Restricted cash			4,144				1,337
Other assets			24,443				18,009
Total assets		$	470,239			$	468,627
Liabilities and stockholders' equity
Current liabilities:
Accounts payable		$	34,033			$	50,020
Accrued compensation			14,573				17,128
Operating lease liabilities, current			7,375				6,218
Other accrued liabilities			29,361				28,508
Customer advances			12,197				13,988
Deferred revenue			82,306				71,649
Short-term debt, net of unamortized financing costs			15,583				7,756
Total current liabilities			195,428				195,267
Noncurrent liabilities
Operating lease liabilities, non-current			32,482				32,373
Long-term other liabilities			5,160				7,389
Warrant liability			8,497				-
Deferred revenue			26,566				24,114
Long-term debt, net of unamortized financing costs			120,937				164,400
Total liabilities			389,070				423,543
Stockholders' Equity:
Common stock			113				100
Additional paid-in capital			602,165				566,887
Accumulated other comprehensive loss			(1,837)				(4,222)
Accumulated deficit			(519,272)				(517,681)
Total stockholders' equity			81,169				45,084
Total liabilities and stockholders' equity		$	470,239			$	468,627

 

Accuray Incorporated Summary of Orders and Backlog (in thousands) (Unaudited)
		Three Months Ended June 30,								Twelve Months Ended June 30,
		2025				2024				2025				2024
Gross orders		$	84,741			$	95,472			$	288,035			$	342,148
Net orders			45,282				63,773				177,233				210,914
Order backlog			426,972				487,319				426,972				487,319
Book to bill ratio (a)			1.2				1.2				1.2				1.5

(a) Book to bill ratio is defined as gross orders for the period divided by product revenue for the period

 

Accuray Incorporated Reconciliation of GAAP Net Income (Loss) to Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization, Stock-Based Compensation and Other (Adjusted EBITDA) (in thousands)
		Three Months Ended June 30,								Twelve Months Ended June 30,
		2025				2024				2025				2024
GAAP net income (loss)		$	1,123			$	3,387			$	(1,591)			$	(15,545)
Depreciation and amortization (a)			1,598				1,507				6,150				5,905
Stock-based compensation			2,818				2,042				10,201				9,483
Interest expense, net (b)			3,937				2,686				11,762				10,676
Gain on extinguishment of debt			(1,475)				—				(1,475)				—
Provision for income taxes			948				471				2,725				3,725
Loss from change in fair value of warrant liability			499				—				499				—
Restructuring charges			—				—				—				2,633
ERP and ERP related expenditures			—				—				—				2,815
Adjusted EBITDA		$	9,448			$	10,093			$	28,271			$	19,692

(a) Consists of depreciation, primarily on property and equipment, as well as amortization of intangibles.

(b) Consists primarily of interest expense associated with outstanding debt.

 

Accuray Incorporated Forward-Looking Guidance Reconciliation of Projected Net Loss to Projected Adjusted Earnings Before Interest, Taxes, Depreciation, Amortization, Stock-Based Compensation (Adjusted EBITDA) (in thousands)
		Twelve Months Ending June 30, 2026
		From				To
GAAP net loss		$	(12,000)			$	(8,000)
Depreciation and amortization (a)			6,000				6,000
Stock-based compensation			10,500				10,500
Interest expense, net (b)			23,500				23,500
Provision for income taxes			3,000				3,000
Adjusted EBITDA		$	31,000			$	35,000

(a) Consists of depreciation, primarily on property and equipment as well, as amortization of intangibles.

(b) Consists primarily of interest expense associated with outstanding debt.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-reports-fourth-quarter-and-fiscal-2025-financial-results-302529237.html

SOURCE Accuray Incorporated

FAQ

What were Accuray's (ARAY) Q4 2025 earnings results?

Accuray reported Q4 2025 revenue of $127.5 million (down 5% YoY) and net income of $1.1 million ($0.01 per share), compared to $3.4 million in the prior year period.

What is Accuray's revenue guidance for fiscal year 2026?

Accuray expects FY26 total net revenue between $471 million to $485 million and adjusted EBITDA between $31 million to $35 million.

How did Accuray's service revenue perform in fiscal 2025?

Service revenue showed strong performance, growing 4% to reach $220.9 million for the full fiscal year 2025, compared to $212.4 million in the prior year.

What was Accuray's order backlog as of June 30, 2025?

Accuray's ending order backlog was $427.0 million as of June 30, 2025, representing a 12.4% decrease from the prior fiscal year.

How much cash does Accuray have on its balance sheet?

As of June 30, 2025, Accuray had $58.0 million in cash, cash equivalents, and short-term restricted cash, a decrease of $20.8 million from March 31, 2025.